Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00394537|
Recruitment Status : Completed
First Posted : November 1, 2006
Last Update Posted : June 6, 2007
Passing a bronchoscope through the airways frequently causes a stress response even though patients are sedated. This stress response is usually an increase in pulse and blood pressure, which may have undesirable effects on the heart and circulation.
We plan to give patients labetalol (a beta blocker which reduces pulse and blood pressure) in addition to normal sedation, to patients undergoing bronchoscopy in our department.
|Condition or disease||Intervention/treatment||Phase|
|Bronchoscopy||Drug: Labetalol 10mg iv||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||72 participants|
|Intervention Model:||Parallel Assignment|
|Actual Study Completion Date :||May 2007|
- Heart Rate
- Systolic Blood Pressure
- Diastolic Blood Pressure
- Rate pressure product (HR*SBP/100)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00394537
|Rabin Medical Center|
|Petach Tikva, Israel, 49100|
|Principal Investigator:||Mordechai Kramer, MD||Rabin Medical Center|